Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

The BioWorld Insider Podcast
16/06/2021 12 min Temporada 1 Episodio 2
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

Listen "Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal"

Descargar episodio Ver en sitio original

Episode Synopsis

Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal.   Hosted on Acast. See acast.com/privacy for more information.

More episodes of the podcast The BioWorld Insider Podcast

Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO 29/08/2025
Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – VIDEO 27/08/2025
The importance of balancing AI and people in drug development 27/05/2025
Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position 23/04/2025
As biopharma investments stumble, med tech surges 30/03/2025
Mega money well spent? Mammoth mergers fall short of the dream 24/02/2025
Healing the health divide for women 22/11/2024
Modifi gets creative on the rocky road to a multibillion-dollar buyout 13/11/2024
A quantum leap into the future of drug development 17/10/2024
Gene and cell therapies will propel innovation, says Astellas CCO 07/10/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA